Kristina Maria Hachey Purchases 90,000 Shares of Theralase Technologies Inc. (CVE:TLT) Stock

Share on StockTwits

Theralase Technologies Inc. (CVE:TLT) Senior Officer Kristina Maria Hachey acquired 90,000 shares of the company’s stock in a transaction dated Monday, May 3rd. The shares were bought at an average cost of C$0.22 per share, with a total value of C$19,800.00. Following the purchase, the insider now owns 1,706,267 shares in the company, valued at C$375,378.74.

Shares of CVE TLT traded up C$0.01 on Tuesday, reaching C$0.22. 247,900 shares of the company traded hands, compared to its average volume of 353,582. Theralase Technologies Inc. has a fifty-two week low of C$0.12 and a fifty-two week high of C$0.32. The company has a 50 day moving average of C$0.26 and a 200 day moving average of C$0.22. The company has a current ratio of 10.86, a quick ratio of 10.21 and a debt-to-equity ratio of 1.07. The stock has a market capitalization of C$44.94 million and a PE ratio of -5.24.

Theralase Technologies Company Profile

Theralase Technologies Inc, a clinical stage pharmaceutical company, engages in the research and development of photo dynamic compounds (PDCs) and their associated drug formulations to treat cancer in Canada, the United States, and internationally. The company also designs, develops, manufactures, and commercializes medical laser systems and other technologies for the activation of PDCs; designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions.

Read More: Technical Analysis

Insider Buying and Selling by Quarter for Theralase Technologies (CVE:TLT)

Receive News & Ratings for Theralase Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theralase Technologies and related companies with's FREE daily email newsletter.